Retatrutide + Tirzepatide: Two Studied Molecules, One Unstudied Pairing

What is the retatrutide + tirzepatide blend?

It is a research preparation supplying two separate synthetic peptides in a single vial. The supplier lists exactly one presentation: tirzepatide 40 mg plus retatrutide 20 mg, 60 mg total per vial. That 2:1 mass ratio is a packaging specification and nothing more — no published work establishes any ratio between these molecules as meaningful, so the number describes what is in the vial rather than any studied relationship.

The two components belong to the same pharmacological family, which makes this pairing different in character from an unrelated-mechanism blend. Both are engineered incretin-class peptides; their receptor targets overlap:

• Tirzepatide (LY3298176) — a dual agonist at the GIP receptor and the GLP-1 receptor, built on a GIP-based backbone with aminoisobutyric acid substitutions and a C20 fatty-diacid side chain. Introduced to the literature by Coskun et al. (2018, Molecular Metabolism). Approved as a medicine. Full detail on the tirzepatide research page.
• Retatrutide (LY3437943) — a triple agonist adding the glucagon receptor to those same two targets, described by Coskun et al. (2022, Cell Metabolism). Investigational; not approved by any regulator. Full detail on the retatrutide research page.

Read plainly, that means retatrutide’s receptor targets already include both of tirzepatide’s. The two are not complementary agents addressing separate systems; they are overlapping agents from one design lineage, developed by the same company. Whether combining overlapping agonists produces anything at all is exactly the sort of question a study would have to answer, and no study has asked it.

For a cross-class comparison of these molecules by receptor target — single versus dual versus triple — see retatrutide vs semaglutide vs tirzepatide, which handles that comparison and is not restated here.

Reference data — per component

Given per component, because a blend has no molecular identity of its own. Values are drawn from the public chemical record and the discovery literature. Retatrutide has no PubChem compound record and no published residue sequence, molecular formula or CAS number that could be sourced here; those fields are omitted rather than estimated, and that absence is itself informative about how early this molecule is.

The shared C20 fatty-diacid strategy is worth noting analytically as well as chemically: two peptides of similar size, similar design and similar hydrophobicity are harder to resolve chromatographically than two dissimilar ones. The verification section returns to this.

What each molecule's own trial programme investigated

Both literatures are substantial and both are summarised only briefly here, with each page carrying the detail. Every line describes what a trial set out to measure, attributed to its investigators.

Tirzepatide

Two large phase 3 programmes: SURPASS in type 2 diabetes and SURMOUNT in obesity, both run by Eli Lilly. The molecule is approved — as Mounjaro in 2022 and Zepbound in 2023 — which makes it the only component of any blend in this catalogue that carries a regulatory approval in its own right. Its pharmacokinetics have been characterised in published work, with a reported half-life of roughly five days. See the tirzepatide page.

Retatrutide

A phase 2 record rather than a phase 3 one at the time of writing: Jastreboff et al. (2023, NEJM) reported the phase 2 obesity trial, and further phase 2 work covered type 2 diabetes and metabolic dysfunction–associated steatotic liver disease. The phase 3 TRIUMPH programme is ongoing. Retatrutide remains investigational. See the retatrutide page.

Two observations follow that are relevant to the vial rather than to either molecule. First, both literatures describe manufactured pharmaceuticals administered under medical supervision in registered trials; neither describes research-grade supplied material, and no property of a reagent can be inferred from them. Second, the two programmes are at different maturities — one approved, one mid-development — so even a reader inclined to reason informally from the components is reasoning from two unequal evidence bases.

Is there any published study of the combination? A documented check

Because this is the question that decides how the page should be read, the check is reported rather than asserted. In July 2026:

• PubMed — retatrutide AND tirzepatide returns 85 records; restricting to those additionally mentioning combination, coadministration or combined returns 33. Inspection of the leading records shows what they are: network meta-analyses of incretin therapies, living systematic reviews, narrative reviews of anti-obesity pharmacology. A network meta-analysis places molecules in a comparison graph; it does not administer them together.
• Europe PMC — title-level search for both names returns seven records, including preprints: comparative-efficacy analyses and animal studies comparing the molecules side by side. None administers both.
• ClinicalTrials.gov — three registered studies mention both. One is a master protocol evaluating multiple agents separately; one is an exercise study in people on GLP-1 therapy; the third is TRIUMPH-5 (NCT06662383), a phase 3 Eli Lilly trial of “retatrutide compared to tirzepatide” in adults with obesity, roughly 800 participants, active and not recruiting. Zero studies administer the two together.

TRIUMPH-5 deserves a sentence of its own because it is the record most likely to be misread. A head-to-head trial randomises each participant to one molecule; the entire design depends on no participant receiving both. It is the strongest evidence that the sponsor of both molecules is interested in which one performs better — and it is not, in any sense, evidence about a combination.

So: no study of the retatrutide and tirzepatide combination exists. Putting them in one vial is a supplier packaging decision. This page makes no claim that the two act together, offers no comparison between the pairing and either molecule alone, and states no combined property — because none has been measured.

There is a further reason the absence is unsurprising here, specific to this pairing. When two agonists share receptor targets, an experiment has to control for the shared engagement before anything can be attributed to the pairing at all — otherwise the design cannot distinguish a combination effect from simply more agonism at the same receptors. That is a demanding trial to build, it has not been built, and until it is, nothing about the pharmacology of this pair is known.

Evidence status and what is not established

What is established: two molecules with published discovery papers, characterised receptor pharmacology and registered trial programmes, one of them approved as a medicine. That is a genuinely strong evidence base — for two molecules, separately.

What is not established: (1) anything whatsoever about the two administered together, for the reasons documented above; (2) any pharmacokinetic behaviour of the pair, which cannot be inferred by adding two single-agent profiles, particularly for two albumin-binding peptides; (3) any safety characterisation of the combination, since safety data belongs to the studied intervention and there is no studied intervention here; and (4) any property of research-grade supplied material, which is not the manufactured product either trial programme used.

Retatrutide is investigational and approved by no regulator. Tirzepatide is approved as a medicine — but a supplied research reagent is not that medicine and inherits none of its regulatory status or clinical data. No combination of the two has been submitted to or reviewed by any regulator anywhere. Material described here is a laboratory research reagent: not a medicine, not for human or veterinary use, with no dosing, preparation-for-use or administration guidance given.

How to verify this compound yourself

This is a harder analytical problem than most blends, and the reason is chemical rather than procedural: the two components are similar in size, similar in design and similar in hydrophobicity.

• Co-elution is the real risk. Two roughly 39-residue peptides, each carrying a C20 fatty-diacid side chain, will behave similarly on a reversed-phase column. If the method does not resolve them, a purity percentage is meaningless — it may be reporting one merged peak as though it were a single pure compound. A certificate for this preparation should demonstrate resolution before it reports purity.
• Mass spectrometry has to carry the identity burden. With chromatographic separation difficult, mass confirmation of both components becomes the primary identity check. Tirzepatide’s expected average mass is roughly 4813 Da. Retatrutide’s is not published in a form this page can state, which means an independent reader cannot fully check that half of the identity claim against a public record — a genuine limitation, stated rather than papered over.
• Content per component. A vial specified as 40 mg + 20 mg requires two quantitation results. Purity does not answer how much of each peptide is present, and the 2:1 ratio is precisely the sort of claim that only per-component quantitation can support.
• Endotoxin and sterility — where tested, independent quality attributes reported separately from chemical purity.

On how often this class fails basic checks: a 2026 preprint by Mendias and Awan analysed 6,441 samples across fourteen compounds, retatrutide and tirzepatide among them, from a large public independent-testing dataset. Between 41.6% and 71.1% of samples failed basic quality criteria depending on which of two acceptance frameworks was applied, and measurable endotoxin was present in 15%. It is a preprint and has not completed peer review; it is cited because it is the largest published look at this exact material class.

See how to read a COA, how to verify peptide purity and how to spot a fake COA. Check the exact batch on the self-serve verify tool.

Research-grade sourcing and verification

This preparation is not held in Cellworks stock. It appears in the sourcing catalogue as available to order in the single 60 mg presentation the supplier lists. Sourcing takes roughly two to three weeks, no price is quoted until availability is confirmed, and there is no cart button.

Anything sourced is a laboratory research reagent with a per-batch Certificate of Analysis. For a two-component vial the certificate has to do the work set out above; a single unattributed purity figure does not characterise this material.

Frequently asked questions

Literature cited

1. Coskun T, Sloop KW, Loghin C, et al. “LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept.” Mol Metab. 2018;18:3–14. PMID 30473097. pubmed.ncbi.nlm.nih.gov/30473097. (Tirzepatide component.)
2. Coskun T, Urva S, Roell WC, et al. “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept.” Cell Metab. 2022;34(9):1234–1247.e9. PMID 35985340. pubmed.ncbi.nlm.nih.gov/35985340. (Retatrutide component.)
3. Jastreboff AM, Kaplan LM, Frías JP, et al. “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” N Engl J Med. 2023;389(6):514–526. PMID 37366315. pubmed.ncbi.nlm.nih.gov/37366315.
4. ClinicalTrials.gov. “TRIUMPH-5: A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity.” NCT06662383 (Eli Lilly; phase 3; ~800 participants; head-to-head, not a combination).
5. Mendias CL, Awan TM. “Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance.” Preprints (not peer reviewed). 2026. doi.org/10.20944/preprints202604.1748.v1.
6. National Center for Biotechnology Information. “PubChem Compound Summary for CID 156588324, Tirzepatide.” pubchem.ncbi.nlm.nih.gov/compound/156588324 (formula, mass, CAS 2023788-19-2).
7. Damen JAA, et al. “Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis.” Ann Intern Med. 2026. PMID 42296503. pubmed.ncbi.nlm.nih.gov/42296503. (Example of a record naming both molecules while comparing, not combining, them.)